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ARTICLE
Maladaptive activation of Nav1.9 channels by nitric
oxide causes triptan-induced medication
overuse headache
Caroline Bonnet1, Jizhe Hao1, Nancy Osorio1, Anne Donnet2, Virginie Penalba1, Jérôme Ruel1 & Patrick Delmas1
Medication-overuse headaches (MOH) occur with both over-the-counter and pain-relief
medicines, including paracetamol, opioids and combination analgesics. The mechanisms that
lead to MOH are still uncertain. Here, we show that abnormal activation of Nav1.9 channels
by Nitric Oxide (NO) is responsible for MOH induced by triptan migraine medicine. Deletion
of the Scn11a gene in MOH mice abrogates NO-mediated symptoms, including cephalic and
extracephalic allodynia, photophobia and phonophobia. NO strongly activates Nav1.9 in dural
afferent neurons from MOH but not normal mice. Abnormal activation of Nav1.9 triggers
CGRP secretion, causing artery dilatation and degranulation of mast cells. In turn, released
mast cell mediators potentiates Nav1.9 in meningeal nociceptors, exacerbating inﬂammation
and pain signal. Analysis of signaling networks indicates that PKA is downregulated in tri-
geminal neurons from MOH mice, relieving its inhibitory action on NO-Nav1.9 coupling. Thus,
anomalous activation of Nav1.9 channels by NO, as a result of chronic medication,
promotes MOH.
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Chronic headache encompasses many different headachediagnoses and include chronic migraines, chronic tension-type headaches, medication-overuse headaches (MOH),
and other types of daily persistent headaches. Migraine, a fre-
quently incapacitating neurovascular disorder, affects hundreds of
millions of individuals worldwide1. It is characterized by a severe,
debilitating and throbbing unilateral headache accompanied by a
host of neurological symptoms including hypersensitivity to
visual and auditory stimulation, nausea and vomiting, and a
variety of autonomic, cognitive and motor disturbances2,3.
Current antimigraine drugs target trigeminovascular 5-HT1B/
1D, 5-HT1F, and CGRP receptors. These different antimigraine
medications induce adverse side effects, including MOH, which is
a worldwide health problem with a prevalence range of 1–2%
with a 3:1 female to male ratio. MOH is a severe form of headache
where the patients are prone to develop primary headaches with
unsuccessful treatments. Patients with migraine or tension-type
headaches have a higher potential for developing MOH than
other primary headaches. MOH does not develop in persons
without a history of headache when medication is being used for
other conditions, such as inﬂammatory diseases. In addition,
virtually all medication for headaches may lead to MOH,
including opioids, ergotamine, butalbital-containing medicine,
triptans or a combination thereof. Thus, MOH is generated in
headache-prone persons by the interaction between headache
medication and pre-existing headache disorder pathways.
The precise mechanisms that lead to MOH development are
largely unknown. However, multiple factors may be implicated,
including genetic predisposition, sensitization within the
trigeminal (TG) system, abnormal cortical pain processing
and decreased antinociceptive activity of the supraspinal struc-
tures4–7.
Multiple studies indicate that migraine medication induces
sensitization of peripheral and central pain pathways. For
instance, chronic use of opioids and triptans in animals has been
shown to increase the level of calcitonin gene-related peptide
(CGRP), which is involved in neurogenic inﬂammation and
headache pain8,9. These animals develop a persistent hypersen-
sitivity or latent sensitization to provocative triggers, such as
environmental stress stimulus and the well-known human
migraine trigger nitric oxide (NO). This latent sensitization per-
sists long after discontinuation of drug administration and pro-
duce a state of generalized cutaneous allodynia that was detected
in periorbital regions and hind paw.
To probe molecular mechanisms that lead to MOH, we
developed a MOH mouse model based on the sustained admin-
istration of sumatriptan, a 5-HT receptor agonist selective for 5-
HT1D and 5-HT1B subtypes. We applied the MOH model to
transgenic mice for studying the role of the nociceptor-speciﬁc
voltage-gated Nav1.9 channel in headache. The function of this
channel in the TG pain pathway is still poorly understood10–12.
Nav1.9 channel is known to generate a persistent, tetrodotoxin
(TTX)-resistant Na+ current that promotes sustained neuronal
activity in dorsal root ganglion (DRG) neurons13–17. Nav1.9 is
known to contribute to both inﬂammatory18–22 and
neuropathic22,23 somatic pain in animal models, and variants of
the Scn11a gene encoding Nav1.9 in humans lead to congenital
insensitivity to pain and to painful syndromes24–27.
Using molecular, electrophysiological, and behavioral approa-
ches, we show that mice chronically treated with sumatriptan
display increased responsiveness of Nav1.9 to NO, leading to
headache/migraine-like symptoms including generalized allody-
nia, photophobia, and phonophobia. MOH mice show deﬁcit in
PKA-mediated inhibition of NO–Nav1.9 coupling, causing
hyperactivity of meningeal nociceptors and inﬂammation in the
meninges. Thus, our data identify abnormal activation of Nav1.9
by NO as a central determinant of triptan-induced MOH and
pave the way for the development of mechanism-based treatment
strategies that can improve the management of primary
headaches.
Results
Nav1.9 is expressed in meningeal nociceptors. Immunostaining
of mouse TG cryosections indicated that Nav1.9 is expressed in
32% of TG neurons (Fig. 1a). Nearly all immunopositive neurons
(96%, n= 174) exhibited small-diameter or medium-diameter
cell bodies (<27 µm, average largest diameter ⌀= 17.4 ± 0.3 µm)
(Fig. 1b), while a minority of them (3.8%, n= 7 out of 181)
displayed large cell bodies (⌀ ≥ 27 µm). Small peripherin-positive
ﬁbers showed features of apposition with meningeal arteries in
whole mount of mouse dura mater (Supplementary Fig. 1A).
Dual-labeling showed that 89% (n= 124/139) and 91% (n= 101)
of peripherin-positive meningeal ﬁbers were immunoreactive for
Nav1.9 and CGRP, respectively (Fig. 1c, d), suggesting that
Nav1.9 and CGRP co-distribute in a large proportion of menin-
geal ﬁbers. Double-labeling for Nav1.9 and CGRP could not be
made due to the different ﬁxation conditions of primary anti-
bodies. However, the quasi-totality of β-gal -positive TG neurons
exhibited CGRP staining in cryosections from Scn11a-GAL
reporter transgenic mice (n= 63/64) (Supplementary Fig. 1B).
Few Nav1.9-positive meningeal ﬁbers were also found to be
immunoreactive for NF200, possibly corresponding to some
lightly myelinated sensory ﬁbers (Supplementary Fig. 1C, D). A
majority (57%) of retrogradely labeled (DiI) dural afferent neu-
rons was found to express Nav1.9 current using patch clamp
recording (Fig. 1e, g). Consistently, 54% of DiI+-dural afferent
neurons from Scn11a-GAL reporter transgenic mice exhibited β-
gal enzymatic activity (Fig. 1f, g). Together, these data provide
evidence that about half of dural afferent neurons expresses
functional Nav1.9 channels.
Scn11a gene inactivation abrogates NO-induced allodynia in
MOH mice. To probe the role of Nav1.9 channels in MOH, we
developed a model of MOH in Nav1.9−/− mice and their wild-
type (WT) littermates using triptan medicines and assessed
quantitatively behavioral correlates of headache and migrainous
symptoms, including generalized allodynia, photophobia, and
phonophobia. Osmotic minipump infusion of sumatriptan in
WT mice for 6 days (0.6 mg/kg/day) produced a time-
dependent reduction in mechanical withdrawal thresholds of
the hind paw relative to saline-treated WT mice (Fig. 2a).
Recovery of paw sensory thresholds to sumatriptan pre-
infusion values occurred within 18–20 days after minipump
implantation (Fig. 2a). Latent sensitization to the migraine
trigger NO was tested at day 21, once sensory thresholds were
returned to pre-sumatriptan baseline levels (Fig. 2b). Injection
of the NO donor sodium nitroprusside (SNP, 0.03 mg/kg) into
the loose skin over the neck evoked strong extracephalic tactile
allodynia in sumatriptan-treated WT mice compared with
saline-treated WT mice (Fig. 2b). Heightened SNP-induced allo-
dynia in sumatriptan-treated WT mice was still observable up to
46 days after minipump implantation (Supplementary Fig. 2A).
Heightened mechanical allodynia induced by SNP injection at day
21 was absent in sumatriptan-treated Nav1.9−/− mice (Fig. 2d).
Moreover, saline-treated Nav1.9−/− and WT mice displayed
similar SNP-induced (basal) allodynia (Fig. 2b, d), indicating that
Nav1.9 contributes to the SNP-induced heightened allodynia in
sumatriptan-treated WT mice, but plays no apparent role in SNP-
induced basal allodynia in saline-treated animals.
Because females have increased risk of developing migraine
and MOH, we tested whether infusion of sumatriptan for 6 days
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(0.6 mg/kg/day) produced mechanical hypersensitivity and latent
sensitization to NO in WT female mice as observed for the
opposite gender. Chronic sumatriptan produced a strong
reduction in mechanical withdrawal thresholds of the hind paw
relative to saline-treated WT female mice and to sumatriptan-
treated Nav1.9−/− female mice (Supplementary Fig. 2B). Injec-
tion of SNP (0.03 mg/kg) at day 21 once sensory thresholds had
returned to pre-sumatriptan baseline values caused signiﬁcantly
stronger mechanical allodynia in sumatriptan-treated WT female
mice compared to saline-treated WT female mice (Supplementary
Fig. 2C). SNP-induced heightened mechanical allodynia was
absent in sumatriptan-treated Nav1.9−/− female mice (Supple-
mentary Fig. 2D), reaching similar amplitude to that caused by
SNP in saline-treated Nav1.9−/− female mice (Supplementary
Fig. 2D). This series of experiments shows that Nav1.9, as
observed in male mice, had no role in SNP-induced allodynia in
saline-treated animals, but contributes to the heightened SNP
allodynia in sumatriptan-treated female mice.
SNP injection at day 21 was also found to reduce mean
periorbital von Frey thresholds (periorbital allodynia) in
sumatriptan-treated WT male mice compared with saline-
treated WT male mice (Fig. 2e). Deletion of Nav1.9 signiﬁcantly
attenuated the SNP-induced periorbital allodynia in sumatriptan-
treated animals (Fig. 2e). Altogether, these data indicate that
Nav1.9 contributes to NO-induced cephalic and extracephalic
tactile allodynia in MOH mice.
Lack of NO-induced visual and auditory symptoms in Nav1.9
KO mice. Besides pain, disabling symptoms of MOH often
include photophobia and/or phonophobia28. To evaluate light-
aversive behavior (photophobia) of mice after SNP injection, we
used the light–dark transition test29. Two hours after SNP
injection, sumatriptan-treated WT mice spent signiﬁcantly more
time in the dark chamber relative to saline-treated WT mice
(Fig. 3a). Sumatriptan-treated Nav1.9−/− mice challenged with
SNP showed no signs of photophobia as the animals spent no
more time in the dark box than saline-treated WT or Nav1.9−/−
mice treated likewise (Fig. 3a).
We further quantiﬁed the sound sensitivity (phonophobia) of
mice following SNP injection by measuring the intensity of sound
required to induce the acoustic startle reﬂex (ASR). We exposed
mice to pseudo-random order of 100 ms-long white noise bursts
ranging from 60 to 120 dB SPL at 10 kHz. The ASR threshold
of saline-treated WT mice injected with SNP was 97 ± 2 dB SPL
(n= 7), which was signiﬁcantly different than that of sumatriptan-
treated WT mice, which showed a lower ASR threshold of 90 ± 1.5
dB SPL (n= 6) (Fig. 3b). Because one decibel equals 10 times the
common logarithm of the power ratio, a decrease in ~10 dB SPL in
ASR corresponds to a 10-fold increase in sound sensitivity. SNP
induced no changes in ASR threshold in sumatriptan-treated
Nav1.9−/− mice compared to saline-treated Nav1.9−/− mice
(Fig. 3b). We then examined the prepulse inhibition (PPI) of the
ASR. This response provides an operational measure of
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Fig. 1 Nav1.9 is expressed in meningeal nerve ﬁbers and dural afferent neurons. a Cryosections of a mouse TG were double-labeled for peripherin and
Nav1.9. Images are projections of seven consecutive optical sections spanning 9 µm. Rightmost panel: merged image. b Histogram showing the distribution
of TG neurons immunopositive for peripherin (green), Nav1.9 (red), or both (yellow) as a function of cell body diameter (⌀). Bin size= 3 µm. c Mouse
whole-mount of dura mater was double-labeled for peripherin and Nav1.9. Images are projections of 16 consecutive optical sections spanning 22 µm.
Rightmost panel: merged image. d Immunostaining for CGRP and peripherin in mouse dura mater. Images are projections of 21 consecutive optical sections
spanning 23 µm. Rightmost panel: merged image. e Left panel: TG neurons cultured 2 days after DiI application through a cranial window in the parietal
bone. Right panel: recording of Nav1.9 current in the retrogradely labeled TG neuron indicated by an arrow. The current was evoked by 100ms-voltage
steps from −80 to −5mV from a Vh of −100mV. CsF-containing patch pipette solution. f Image from a Scn11alacZ mouse showing β-galactosidase
expression (dark dots) in DiI+ afferent neurons (red) from the TG. g Histogram showing the percentage of DiI+ afferent neurons exhibiting Nav1.9 current
(patch clamp) or β-galactosidase (staining)
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sensorimotor gating reﬂecting the sensitization of mice to weak
sounds30. PPI was measured as the innate reduction of the startle
reﬂex induced by a weak pre-stimulus sound (Fig. 3c). Following
SNP injection at day 21, the PPI value was 18.5 ± 2% in saline-
treated WT mice but reached 42.4 ± 2.5% in sumatriptan-treated
WT mice (Fig. 3c, d), indicating sensitization to sounds. By
contrast, the PPI value was not signiﬁcantly different in saline-
treated versus sumatriptan-treated Nav1.9−/− mice (Fig. 3c, d).
Together, these data indicate that Nav1.9 is essential to the
development of NO-induced symptoms of central sensitization
observed in MOH mice.
Triptan overuse promotes coupling of NO-cGMP to Nav1.9
channels. We investigated the molecular basis that promotes
increased sensitivity of MOH mice to NO. Given the difﬁculty to
unambiguously isolate Nav1.9 from Nav1.8 currents when using
CsCl-based pipette solution11,13,14, retrogradely labeled dural
afferent neurons were studied from Nav1.8−/− mice. We pro-
vided evidence that inactivation of the Scn10a gene encoding
Nav1.8 did not affect sumatriptan-induced latent sensitization
and hypersensitivity to SNP in MOH mice (Supplementary
Fig. 3).
Nav1.9 current recorded in dural afferent Nav1.8−/− neurons
cultured at day 21 (i.e. 21 days after pump implantation) was
identiﬁable from its slow activation kinetics and incomplete
inactivation, producing ‘persistent’ TTX-resistant Na+ currents.
Neither the mean Nav1.9 peak current density (Fig. 4b), nor the
level of Nav1.9 mRNA expression (at day 21) (Supplementary
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Fig. 2 Deletion of Nav1.9 prevents NO-induced generalized allodynia in MOH mice. a Infusion of sumatriptan (0.6 mg/kg/day), but not saline solution
(0.9%), decreases withdrawal thresholds to tactile stimuli applied to the hind paws of WT mice. Hind paw withdrawal threshold was tested using von Frey
ﬁlaments (inset). **p < 0.01, ***p < 0.001 compared to saline with Mann–Whitney non-parametric test. Top inset: schematic of mouse treatment over time.
b Changes in mechanical withdrawal thresholds of the hind paws induced by injection of SNP (0.03mg/kg) in WT mice pre-treated (red symbols) or not
(open circles) with sumatriptan. Data illustrated depict SNP responses 21 days after minipump implantation. **p < 0.01, ***p < 0.001 compared to WT
saline, SNP with Mann–Whitney non-parametric test. c Hind paw withdrawal responses of sumatriptan-treated Nav1.9−/− mice compared with
sumatriptan-treated WT littermates. *p < 0.05, **p < 0.01, ***p < 0.001 compared to WT with Mann–Whitney non-parametric test. d Comparison of SNP-
induced changes in hind paw withdrawal thresholds in sumatriptan-treated WT mice (red symbols), saline-treated Nav1.9−/− mice (open squares) and
sumatriptan-treated Nav1.9−/− mice (blue squares). All tests were made at day 21. **p < 0.01, ***p < 0.001 compared to WT sumatriptan with two-way
ANOVA followed by Student–Newman–Keuls test. e Normalized periorbital withdrawal threshold plotted as a function of time after SNP injection in saline-
treated WT mice (open bars), sumatriptan-treated WT mice (red bars) and sumatriptan-treated Nav1.9−/− mice (blue bars). Data illustrated depict SNP
responses 21 days after pump implantation. *p < 0.05, ***p < 0.001; two-way ANOVA followed by Student–Newman–Keuls test
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Fig. 4) was signiﬁcantly different in TG neurons from saline-
treated and sumatriptan-treated mice.
SNP (1 mM) increased Nav1.9 peak current (measured at peak
I–V) by 232 ± 11% (n= 20) in dural afferent neurons from
sumatriptan-treated Nav1.8−/− mice, whereas it had little effect
(72.7 ± 4%, n= 23) in control dural afferent neurons (Fig. 4a, b).
Current–voltage relationships determined before and after SNP
application in sumatriptan-treated dural neurons showed a
22 mV negative shift in activation V1/2 value (from −11.3 ± 1.8
to −32.7 ± 1.02 mV). This shift was also associated with a ~2-fold
increase in Nav1.9 maximum conductance (from −1.28 to −2.64
nS/pF) (Fig. 4c, d). By contrast, SNP induced a ~−6 mV shift in
dural afferent neurons from saline-treated mice (from −14.47 ±
1.3 to −20.8 ± 0.8 mV), which was not associated with change in
Gmax (Fig. 4d).
Because the cyclic guanosine monophosphate (cGMP) signal
pathway plays an important role in NO signaling, we sought to
determine the involvement of the soluble guanylyl cyclase (sGC)
in the activation of Nav1.9. Application of methylene blue (100
µM), a sGC inhibitor, abolished the effect of SNP on Nav1.9 in
dural afferent neurons from sumatriptan-treated Nav1.8−/− mice
(Supplementary Fig. 5). Consistently, the cell-permeable cGMP
analog 8-Br-cGMP (1 mM) strongly increased Nav1.9 current
and negatively shifted V1/2 activation by 19 mV (from −13.5 to
−32.5 mV) in saline-treated Nav1.8−/− mice (Supplementary
Fig. 6A–C). These data indicate that NO-cGMP pathway activates
Nav1.9 in sumatriptan-treated, but not in saline-treated dural
afferent neurons.
Relief of PKA inhibition causes NO coupling to Nav1.9 in
MOH mice. To probe the molecular changes in TG neurons at
day 21 from sumatriptan-treated mice, we made qPCR analysis of
cGMP-linked signaling molecules. Relative mRNA quantiﬁcation
showed there was a three-fold decrease of the transcript of protein
kinase cAMP-activated catalytic subunit alpha (PKA-Cα) but no
changes (0.5 < RQ < 2) for the cyclic nucleotide phosphodies-
terases 3a, 3b and 5a (PDE3a, PDE3b, and PDE5a), the sGC, the
predominant receptor for NO, the Protein Kinase G type I (PKG-
I) and the Adenylyl Cyclase type III (AC-III) (Supplementary
Fig. 7A). Pre-treatment of 8-Br-cAMP, a membrane permeable
cAMP analog, inhibited cGMP-mediated activation of Nav1.9 in
dural afferent neurons from saline-treated mice, although it had
no effect per se on Nav1.9 (Supplementary Fig. 7B–D), indicating
that cAMP can inhibit cGMP coupling to Nav1.9 in TG neurons.
Consistently, we found that DiI+-dural afferent neurons showed
strong staining for the catalytic PKA subunit phospho T197
antibody that recognizes the active form of the PKA protein
(Supplementary Fig. 8A, B). In addition, the mean intensity
(arbitrary unit) per pixel of PKA subunit phospho T197 staining
was signiﬁcantly (p= 0.03, unpaired t-test) reduced from 131 ± 4
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(n= 44 DiI+-neurons) in control mice injected with saline
solution to 118 ± 5 (n= 50 DiI+-neurons) in mice treated with
sumatriptan (data not shown). Changes in PKA expression in
TGs from sumatriptan-treated mice (n= 8) were also evaluated
by quantifying band intensities on phospho T197 PKA blots and
comparing to blot band intensities in saline-treated mice (n= 8)
as controls. Densitometry analysis of background-subtracted blots
from 20 µg of total lysate showed a 22% decrease in phospho
T197 PKA expression in sumatriptan-treated mice versus control
mice (Supplementary Fig. 8C). This decrease however did not
reach signiﬁcant level due to sample variability (Supplementary
Fig. 8D).
Collectively, these data suggest that nitrergic activation of
Nav1.9 in sumatriptan-treated mice may result from a decrease in
PKA activity in dural afferent neurons and subsequent relief of
PKA-mediated inhibition of NO–Nav1.9 coupling.
Nav1.9-mediated hyperexcitability causes central sensitization.
Firing activity of retrogradely labeled dural afferent neurons was
studied at day 21. SNP-mediated Nav1.9 activation converted
phasic discharges into multi-action potential (AP) responses in
78.5% of dural afferent neurons from sumatriptan-treated WT
mice (Fig. 5a–c). In addition, SNP reduced by 35% the current
threshold for ﬁring in neurons from sumatriptan-treated WT
mice (Fig. 5d, e). By contrast, SNP had no signiﬁcant effects on
the ﬁring response and AP current threshold in dural afferent
neurons from saline-treated WT mice (Fig. 5c, d). Moreover, SNP
caused no changes in excitation or AP current threshold in dural
afferent neurons from sumatriptan-treated Nav1.9−/− mice
(Supplementary Fig. 9).
We tested whether Nav1.9-mediated hyperexcitability regulates
the secretion of CGRP, a key player in headache pathogenesis
(Fig. 6a). SNP, at low concentrations, had no signiﬁcant effects on
basal secreted CGRP levels in TG cultures from saline-treated
WT mice but enhanced CGRP secretion (+70%) in TG cultures
from sumatriptan-treated WT mice. Enhanced secretion of CGRP
by SNP was not observed in TG cultures from sumatriptan-
treated Nav1.9−/− mice (Fig. 6a).
The in vivo consequence of Nav1.9-dependent CGRP secretion
was tested on SNP-mediated extracephalic mechanical allodynia
at day 21 using the CGRP antagonist α-CGRP8-37. Injection of
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α-CGRP8-37 (1 mg/kg), but not the vehicle, reduced SNP-induced
extracephalic allodynia in sumatriptan-treated WT mice, indicat-
ing that released CGRP contributes to central sensitization
(Fig. 6b). Importantly, injection of α-CGRP8-37 had no effects on
residual SNP-induced allodynia in sumatriptan-treated Nav1.9−/−
animals (Fig. 6c), providing further evidence that Nav1.9
activation by SNP is a prerequisite for CGRP release from
meningeal nociceptors.
Nav1.9 mediates vasodilatation and mast cell degranulation.
Functional consequences of Nav1.9 activation on meningeal
microcirculation was examined at day 21 using a laser Doppler
blood perfusion scanner. SNP (0.03 mg/kg), injected through
the jugular vein, caused a gradual increase of meningeal blood
ﬂow in sumatriptan-treated WT mice. No change was seen in
saline-treated WT mice and in sumatriptan-treated Nav1.9−/−
mice (Fig. 6d, e). We further tested whether activation of
meningeal nociceptors by SNP causes degranulation of dural
mast cells (MCs) and pain ampliﬁcation through a Nav1.9-
dependent mechanism. The MC stabilizing agent, sodium
cromoglycate (SCG, 10 mg/kg i.p.), injected 30 min prior to
SNP, signiﬁcantly reduced both the intensity and duration of
the SNP-induced heightened allodynia in sumatriptan-treated
WT mice (Supplementary Fig. 10B) but had no signiﬁcant
effects on SNP-induced basal allodynia in saline-treated WT
mice (Supplementary Fig. 10A) and on SNP-induced allodynia
in sumatriptan-treated Nav1.9−/− mice (Supplementary
Fig. 10C).
We ﬁnally sought to determine whether MC degranulation
contributes to dural afferent terminal excitation through
receptor-driven modulation of Nav1.9. Patch clamp recordings
showed that the MC mediators histamine and PGE2 are
powerful activators of Nav1.9 current in dural afferent neurons
(Fig. 7). Superfusion of histamine and PGE2 increased peak
Nav1.9 current by 100.5 ± 25% and 233 ± 40%, respectively, in
saline-treated Nav1.8 KO mice (Fig. 7a–g). Both mediators
caused a substantial leftward shift in the activation curve of
Nav1.9 (Fig. 7c, f) and strongly increased the ﬁring rate of dural
afferent neurons (Fig. 7h, i). These effects were seen irrespective
of the mouse treatment (Fig. 7g). By contrast, CGRP, SP, and
neurokinin A, which are potentially released by meningeal
terminals, had no detectable effects on Nav1.9 current in dural
afferent neurons from either saline-treated or sumatriptan-
treated mice (Supplementary Fig. 11A–D). Thus, some MC
mediators have the capacity to activate Nav1.9, resulting in a
feedforward loop that potentiates neurogenic inﬂammation and
nociceptive transmission. Collectively, these results indicate
that Nav1.9 acts as a hub in meningeal nociceptors and
contributes to maladaptive nociceptive signal, neurogenic
inﬂammation, meningeal vasodilatation, and mast cell degra-
nulation (Fig. 8).
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Discussion
How chronic exposure to abortive medication leads to MOH
remains unclear. Our study suggests that chronic use of triptans
induces MOH through abnormal activation of meningeal Nav1.9
by NO. Thus, triptan-overuse headache derives from Nav1.9
activation in the TG system, triggering pain facilitation through
central and peripheral sensitization and inﬂammation in the
meninges.
The complex pathophysiology behind MOH is still only partly
known. Mechanisms involved may differ from one class of
overused drug to another. Previous studies have shown that
chronic use of opioids and triptans increases CGRP levels which
is well known to be involved in neurogenic inﬂammation and
headache pain8,31. Impaired diffuse noxious inhibitory controls6
and central sensitization are also seen in MOH patients4,32. Many
of these phenomena are similar to mechanisms seen in depen-
dence processes33,34.
Our approach to modeling MOH symptoms was the quanti-
ﬁcation of increased sensory sensitivity in response to NO, one of
the most common reported trigger for headache and
migraine8,9,35,36. NO donors reliably trigger headache in normal
subjects, but trigger migraine and severe pain in migraineurs36,
and this condition is accompanied by an increase in blood levels
of CGRP, which is directly linked to the severity of headache
pain37–39. In our study, MOH following NO infusion was
evaluated using multiple headache-like responses in each indivi-
dual animal, including cutaneous facial and extracephalic allo-
dynia as well as aversion to light and noise. Our data show that
chronic sumatriptan treatment of mice induces a state of dormant
sensitization characterized by sharp, exacerbated sensory
responses to NO8,9,40.
Clinical and preclinical studies have consistently demonstrated
increased excitability of the TG system after medication overuse.
TG neuronal hyperexcitability may facilitate the process of per-
ipheral and central sensitization. We show that NO was capable
of producing strong activation of dural afferent neurons in MOH
mice and that sensory hypersensitivity and MOH-associated
symptoms were prevented by deleting Nav1.9 but not Nav1.8.
Nav1.9 activation sustains the hyperexcitability of meningeal
nociceptors and lowers the threshold response for afferent pain
signaling. Importantly, coupling of NO to Nav1.9 was weak under
normal conditions, consistent with the observation that deleting
Nav1.9 had no impact on SNP-induced (basal) cutaneous allo-
dynia in saline-treated mice. Thus, chronic sumatriptan treatment
promotes coupling of NO to Nav1.9 channels in dural afferent
neurons, thus lowering the threshold of the animal’s susceptibility
to respond to initiating factors of headache. Importantly, we
found that hypersensitivity to SNP was greater in MOH female
than in male mice, which parallels the sexual dimorphism
reported in MOH and migraine in humans.
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What then favors Nav1.9 activation by NO/cGMP in
sumatriptan-treated mice? PKA-Cα transcripts were found to be
down-regulated in TGs from sumatriptan-treated animals at day
21, suggesting that constitutive activity of PKA, in control ani-
mals, inhibits NO–Nav1.9 coupling. This is consistent with the
observation that cAMP pretreatment inhibited cGMP-mediated
activation of Nav1.9 in dural afferent neurons. How chronic
stimulation of Gi-coupled 5HT1B/D receptors, which are
notably expressed in TG neuron plasma membrane41, leads to
long-term changes of PKA gene transcription remains to be
determined.
Genetic deletion of Nav1.9 prevented SNP-induced meningeal
vasodilatation, indicating that Nav1.9-dependent excitation of TG
neurons was a prerequisite for this effect. Thus, Nav1.9 activation
by SNP not only causes hyperexcitability of nociceptors but also
triggers the release of vasoactive neuropeptides in the meninges.
In vitro experiments further indicated that NO-induced release of
CGRP was prevented by deleting Nav1.9. These data indicate that
Nav1.9-dependent release of CGRP, and possibly other neuro-
peptides including SP, plays a pivotal role in the vasodilatation of
meningeal blood vessels. Our data however do not specify whe-
ther the vasodilatation contributes to MOH-related symptoms or
whether this is a side-phenomenon42. Therefore, if vasodilatation
of meningeal arteries contributes to the propagation of the cas-
cade of symptoms, it is likely in conjunction with other factors.
CGRP is also poised to enhance headache pain by central
mechanisms. Consistently, our results show that SNP-induced
extracephalic allodynia was transiently alleviated by acute
administration of the CGRP antagonist α-CGRP8–37 in
sumatriptan-treated animals. Because, extracephalic allodynia is a
manifestation of central sensitization43, these data argue that
Nav1.9-dependent CGRP release may also occurs at postsynaptic
structures, such as the trigeminal nucleus caudalis, activity of
which may sensitize thalamic neurons. These results call for an
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early use of anti-Nav1.9 drugs that target meningeal nociceptors,
before the development of central sensitization.
Our data demonstrate that Nav1.9-mediated release of neuro-
peptides from meningeal nociceptors could trigger degranulation
of dural MCs. CGRP and SP, which are often co-released, are
particularly important in this regard as they are known to sti-
mulate MC degranulation in different systems44. Histamine, a
major amine released from MCs45, and PGE2 another pro-
inﬂammatory MC mediators46, are well-recognized migraino-
genic substances known to induce pain upon infusion into
human subjects diagnosed with migraine. Our data show that
both substances cause a prominent increase of Nav1.9 and pro-
mote neuronal hyperexcitability, resulting in a vicious, self-
reinforcing cycle of sterile inﬂammation and nociception (cf
Fig. 8). Because MCs express a variety of 5-HT receptors, it is
possible that chronic treatment with sumatriptan reinforces the
possibility that MCs respond to peptide-induced degranulation.
However, the reported effects of 5-HT on MCs have generally
been found to be mediated by 5-HT1A and not by 5HT1B/D
receptors47.
In conclusion, our study identiﬁes NO-induced Nav1.9 channel
activation as a triggering mechanism for MOH-related symp-
toms. The way in which medication overuse transforms episodic
migraine into chronic daily headache is still unknown. The pic-
ture that emerges from our study is that abnormal sensitivity of
meningeal Nav1.9 channels to the migraine trigger NO may cause
the headache phase in MOH patients. Activation of Nav1.9 may
be a common denominator of overused drugs and migraine
triggers. Therefore, the use of Nav1.9 channel inhibitors, in
combination with sumatriptan or other headache medications,
may represent a new acute and preventive option for migraine
treatment.
Methods
Animals. This project was approved by the Institutional Review Board of the
regional ethic committee. All animals were used in accordance with the European
Community guiding in the care and use of animals (2010/63/UE). All efforts were
made to minimize the number of animals used and their suffering. Mice (10–12-
week-old adult males and females, C57Bl/6J background) used in this study were
Nav1.9−/−, Nav1.8−/− (gifts from N.J. Wood, see refs. 19,23) and their WT
littermates. The Scn11a-GAL reporter mouse was previously described15. An IRES/
LacZpA cassette followed by a loxP/neo/loxP cassette was inserted into the end of
exon 5 of the Scn11a gene.
Infusion of sumatriptan and injection of SNP. Alzet osmotic minipumps (model
1007D, Charles River, France) with a nominal ﬂow rate of 0.5 μl/h for 6 days were
used for drug infusion. The minipumps were implanted subcutaneously under
anesthesia with isoﬂurane. The day of the pump implant was considered as day 0.
Drugs administered by infusion were sumatriptan (0.6 mg/kg/day, Sigma, St. Louis
USA) and its vehicle (NaCl, 0.9%). SNP was injected subcutaneously into the loose
skin over the neck at 0.03 mg/kg. Infusion of sumatriptan/saline and injection of
SNP/saline were made blind, e.g. the investigator was not aware of the content of
the minipump, nor of the nature of the solution (SNP or vehicle) injected on day
21. Animals were randomly assigned to treatment groups.
Tactile sensory testing. Hind paw mechanical threshold was assessed using von
Frey ﬁlaments (Bioseb, France) as described20. For facial testing, mice were sub-
jected to a von Frey stimulus applied to the forehead surface, repeated three times
(at minimum 30 s interval). The head withdrawal tactile sensory threshold was the
lowest force to elicit withdrawal in 2 of 3 trials. Data points were normalized to the
control sensory threshold values determined just before minipump implantation
(i.e. at day 0) or before SNP injection (i.e. at day 21, H0).
Light aversive test. To evaluate the light-aversive behavior after SNP injection, we
used a light–dark test. The light-aversion chamber consisted of two equally sized
compartments (10 cm width, 13 cm length, and 13 cm height), one painted white
and lacking a top, the other painted black and fully enclosed. A corridor (7.2 cm
width, 7.2 cm length, and 13 cm height) connects the two compartments. Mice
were acclimatized at least 1 h in their cages in the testing room and were allowed to
explore the light-aversion chamber 10 min before testing. The light-aversive
behavior was examined 2 h after SNP injection (0.03 mg/kg) and during 30 min.
The thermal-neutral ﬁber-optic source is located in the middle of white box and
produces a light intensity of 2600 lx inside the lit area of the white chamber. Mouse
transitions were interpreted to be a reﬂection of light aversion.
Acoustic startle threshold and prepulse inhibition tests. The Startle Reﬂex
System (Bioseb, France) was used to measure the acoustic sensitivity of mice. The
hardware consisted of an isolation cabinet that minimizes the effects of extraneous
noise and vibrations. The startle chamber is situated in the center of the isolation
cabinet (250 (W) × 250 (D) × 250(H) mm) and a restrainer (90 × 30 mm) was used
to restrain minimally the animal during testing. Mice were acclimatized in the
restrainer for 5 min per day, one week before the testing session. Mice were also
acclimatized in their cages in the testing room, 2 h before the testing session.
Acoustic stimuli for behavioral tests were based on previously published studies
deﬁning criteria applicable to mice at around 2 months of age. The waveforms
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Fig. 8 Central role of Nav1.9 in MOH mechanisms. The following scenario summarizes the contribution of Nav1.9 to MOH. NO, which may be released
from different sources, activates Nav1.9 channels in dural afferent neurons from chronically treated mice with triptans. Nav1.9 activation by NO increases
the excitability of meningeal nociceptors, which sensitizes central structures leading to extracephalic allodynia, photophobia, and phonophobia. Nav1.9-
dependent secretion of CGRP in the meninges, possibly in combination with other mediators, causes degranulation of resident mast cells. By releasing
histamine and PGE2, MCs retro-excite meningeal nociceptors through Nav1.9 potentiation. Vasoactive peptides also contribute to vascular relaxation that
may further facilitate endothelial (and possibly extravascular) NO production. The consequence is a vicious circle that leads to enhanced activation of
meningeal nociceptors and maladaptive pain
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generated by the mouse’s movement during the startle response were analyzed
using the Packwin software (Panlab, Inc., Harvard apparatus).
Two hours after SNP injection, the mouse was acclimatized for 5 min in the
presence of a background noise level of 60 dB SPL. The mouse was then exposed to
random trials of white noise bursts ranging from 60 to 120 dB SPL at 10 kHz,
frequency that falls within the most sensitive region of the mouse audiogram. Each
sound intensity was presented three times. The ASR threshold was taken as the
minimum intensity required to elicit a response in two out of third trials. The PPI
is a reliable, robust quantitative phenotype that is useful for probing sensory
functions. Testing consisted of a series of 115 dB SPL-test pulses immediately
preceded or not by a prepulse of 70 dB SPL at 10 kHz. PPI was calculated as
follows: PPI (%)= (1–(startle response with prepulse)/(startle response without
prepulse)) × 100.
Cultures of TG neurons. Mice were anesthetized at day 21 with isoﬂurane and
killed by decapitation. TGs were dissected out and freed from their connective
tissue sheaths. TG neurons were incubated in enzyme solution containing 2 mg/ml
of collagenase IA (Sigma) for 45 min at 37 °C. The tissue was washed several times
and triturated in Hanks’ balanced salt solution. The resulting suspension was ﬁl-
tered (70 µm ﬁlters) and centrifuged (800×g for 5 min) and plated on poly-L-lysine/
laminin (0.05 and 0.01 mg/ml, respectively) coated Nunclon dishes. Culture
medium was Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% heat-
inactivated FCS, 100 U/ml penicillin–streptomycin, 2 mM L-glutamine, 25 ng/ml
nerve growth factor (NGF), and 2 ng/ml glial-derived neurotrophic factor (GDNF).
Patch clamp recordings. Patch pipettes had resistances of 2 MΩ. Voltage clamp
recordings of Na+ currents used the following intracellular solutions: (CsF-con-
taining, in mM), 30 CsF, 100 CsCl, 10 HEPES, 10 EGTA, 8 NaCl, 1 MgCl2, 1 CaCl2,
4 MgATP, 0.4 Na2GTP (pH 7.35, 300 mOsm/l); (CsCl-based, in mM), 130 CsCl,
10 HEPES, 10 EGTA, 8 NaCl, 1 MgCl2, 1 CaCl2, 4 MgATP, 0.4 Na2GTP (pH 7.35,
300 mOsm/l). The extracellular solution contained (in mM): 60 NaCl, 110 sucrose,
3 KCl, 1 MgCl2, 10 HEPES, 2.5 CaCl2, 10 glucose, 10 TEA–Cl, 0.0005 TTX,
1 amiloride, 0.05 La3+ (pH 7.4, 305 mOsm/l). For current clamp recording, the
intracellular solution (KCl-based) consisted of (mM): 115 KCl, 10 HEPES,
10 EGTA, 8 NaCl, 1 MgCl2, 1 CaCl2, 4 MgATP, 0.4 Na2GTP. The extracellular
solution consisted of (in mM) 131 NaCl, 3 KCl, 1 MgCl2, 10 HEPES, 2.5 CaCl2,
10 glucose (pH 7.4, 305 mOsm/l). All chemicals were from Sigma-Aldrich, except
TTX (Alomone Labs).
PCLAMP 9.2 (Axon Instruments Inc.) and PRISM 4.0 (GraphPad) software suites
were used to perform linear and nonlinear ﬁtting of data. Conductance–voltage curves
were calculated from the peak current according to the equation G= I/(V−Erev),
where V is the test pulse potential and Erev the reversal potential calculated according
to the Nernst equation. The activation curve (G−V) was ﬁtted using the Boltzmann
function: G/Gmax= 1/(1+ exp[(V1/2−V)/k]), where G/Gmax is the normalized
conductance, V1/2 is the potential of half-maximum channel activation, and k is the
steepness factor.
Tracer application onto the dura. Mice were anesthetized with isoﬂurane.
Throughout surgery, the core temperature of the mouse was monitored and
maintained by an homeothermic blanket system for rodents. Two small cranial
windows were made in parietal bones and the retrograde nerve tracer DiI (DiI
tissue labeling paste, Invitrogen) was applied onto the dura. The bone ﬂaps were
then replaced after the procedure with bone wax in order to prevent tracer
spreading. Animals were euthanized for TG extraction 2 days after DiI application.
Tissue preparation, immunostaining, and confocal imaging. For Nav1.9
immunostaining, the tissues were cryoprotected in PBS containing 4% sucrose
during 30 min and then incubated for at least 1 h in PBS plus 20% sucrose at 4 °C.
The TGs were frozen in OCT embedding matrix bathed in chilled isopentane. The
TGs were then sagitally cryosectioned at 14–18 µm, transferred to SuperFrostPlus
slides and stored at −80 °C until processed. Whole mount dura maters were
transferred to SuperFrostPlus slides, frozen on dry ice and stored at −80 °C until
processed. Primary antibodies used and dilutions were as follows: anti-peripherin
1/400 (mouse monoclonal, Millipore, Temecula, CA); anti-NF200 1/400 (chicken
polyclonal, Aves Labs, Tigard, OR); anti-CD31 (1/400, rat polyclonal, BD Bios-
ciences, Belgium); anti-Nav1.9 L23, (1/100, rabbit polyclonal)10; and anti-CGRP (1/
300, goat polyclonal, AbCam).
For CD31 immunostaining, the tissues were ﬁxed for 30 min at room
temperature (RT) in Antigenﬁx (Microm Microtech, France) before being
cryoprotected and frozen as described above. Slides with fresh frozen tissues or
ﬁxed with Antigenﬁx tissues were thawed at RT and then incubated for 90 min at
RT in blocking solution containing 3% BSA and 0.1% Triton X-100. Primary
antibodies were diluted in PBS containing 3% BSA and applied to tissues to be
incubated overnight at 4 °C in sealed humidiﬁed chambers.
For CGRP immunostaining, the tissues were ﬁxed in 4% PFA in PBS for 3 h at
RT then cryoprotected in PBS containing 25% sucrose overnight at 4 °C. The
tissues were transferred to SuperFrostPlus slides, frozen and stored at −80 °C until
processed. Slides with PAF-ﬁxed tissues were thawed at RT and then incubated for
1 h30 min at RT in blocking solution containing 5% ﬁsh gelatin and 0.2% Triton X-
100. CGRP antibodies were diluted in PBS containing 5% ﬁsh gelatin and applied
to tissues to be incubated overnight at RT in sealed humidiﬁed chambers.
After incubation with the primary antibodies, ﬁxed and fresh frozen tissues
were identically proceeded. Tissues were washed three times for 5 min in PBS and
incubated for 45 min at RT with secondary antibodies diluted in blocking buffer.
Secondary antibodies were: Alexa Fluor 647-conjugated donkey anti-mouse (1/400,
Life Technologies), TRITC-conjugated donkey anti-rabbit (1/400, Jackson
ImmunoResearch, Suffolk, UK), TRITC-conjugated donkey anti-rat (1/100,
Jackson ImmunoResearch), Alexa Fluor 488-conjugated donkey anti-goat (1/200,
Life Technologies). After six 5 min-washes in PBS, sections were mounted in
Mowiol (Sigma-Aldrich). Images were acquired using a LSM 780 laser-scanning
confocal microscope (Zeiss), initially processed using ZEN software (Zeiss) and
later exported into Adobe Photoshop (Adobe Systems, San Jose, CA) for ﬁnal
processing.
Staining for beta-galactosidase enzyme activity. Evaluation of β-gal enzymatic
activity was performed on transgenic mice that express β-gal at the Scn11a loci.
Once dissected out, the TGs were slightly ﬁxed 15 min in PBS containing 2% PFA,
0.2% glutaraldehyde, and 2 mM MgCl2. The tissues were washed with two changes
of PBS containing 2 mM MgCl2 for 5 and 8 min. The staining is achieved with an
overnight incubation of TGs in PBS added with 4 mM Ferrocyanide, 4 mM Fer-
ricyanide, 2 mM MgCl2, 1% Tween-20, and 0.2 mg/ml X-gal at 37 °C. The TGs
were ﬁnally post-ﬁxed for 15 min in PBS containing 2% PFA, 0.2% glutaraldehyde,
and 2 mM MgCl2, and washed four times in PBS. The TGs were cryoprotected in
PBS containing 4% sucrose for 30 min and then incubated overnight in PBS plus
20% sucrose at 4 °C. The TGs were then frozen in OCT embedding matrix
(Cellpath, Hemel Hempstead, UK) bathed in chilled isopentane. TGs were then
sagitally cryosectioned at 14–18 µm, transferred to SuperFrostPlus slides (Fisher
Scientiﬁc, Houston, TX), dried at RT and mounted in Mowiol (Sigma-Aldrich).
CGRP staining in TGs from Scn11a-GAL reporter mice. β-gal enzymatic activity
in TGs from Scn11a-GAL reporter transgenic mice was revealed as above, except
that glutaraldehyde was omitted from the ﬁxative solution. Once achieved, TGs
were post-ﬁxed for 2 h in PBS containing 2% PFA and 2mM MgCl2, washed four
times in PBS and then cryoprotected in PBS containing 25% sucrose overnight.
TGs were then frozen in OCT embedding matrix bathed in chilled isopentane and
sagitally cryosectioned at 14–18 µm, transferred to SuperFrostPlus slides, dried at
RT and stored at −80 °C. Slides with TGs were thawed for 15 min at RT and then
incubated for 1 h 30 min at RT in blocking solution containing 3% BSA and 0.1%
Tx-100. CGRP antibody (rabbit polyclonal #PC205L, Millipore) were diluted at 1/
200 in blocking buffer and applied to tissues to be incubated overnight at 4 °C in
sealed humidiﬁed chambers. Tissues were washed three times for 10 min in PBS
and incubated 40 min at RT in PBS containing 3% BSA added with secondary
antibodies Alexa Fluor 488-conjugated donkey anti-rabbit (1/200, Life Technolo-
gies). After successive 5 min washes in PBS, sections were mounted in Mowiol
(Sigma-Aldrich). Images were acquired using a conventional ﬂuorescence micro-
scope (Zeiss Axio-observer) with constant acquisition settings.
Quantitation of anti-PKA immunostaining. The TG ganglia were carefully dis-
sected out from NaCl-treated and sumatriptan-treated mice whose dura were DiI-
stained (see above). The TGs were ﬁxed in 4% PFA in PBS for 2 h 30 min at 4 °C
then cryoprotected in PBS containing 25% sucrose overnight at 4 °C. The TGs were
then frozen in OCT embedding matrix bathed in chilled isopentane and stored at
−80 °C until processed. The day before PKA staining, the TGs were sagitally
cryosectioned at 14 µm, transferred to SuperFrostPlus slides and stored at −80 °C.
Slides with PAF TGs were thawed 15 min at RT and then incubated for 30 min at
RT in blocking solution containing 3% ﬁsh gelatin and 0.05% saponin. PKA
antibodies (rabbit polyclonal #ab75991, AbCam) were diluted at 1/200 in blocking
buffer and applied to tissues to be incubated overnight at 4 °C in sealed humidiﬁed
chambers. Tissues were washed three times for 10 min in PBS and incubated for 3 h
at RT in PBS containing 3% ﬁsh gelatin added with secondary antibodies Alexa
Fluor 488-conjugated donkey anti-rabbit (1/200, Life Technologies). After four
5 min washes in PBS, sections were stained with DAPI, washed once in PBS and
mounted in Mowiol (Sigma-Aldrich).
In order to compare the ﬂuorescence intensities of PKA immunostaining
between NaCl-treated and sumatriptan-treated DiI-positive TG neurons, images
were acquired using a LSM 780 laser-scanning confocal microscope (Zeiss) using
constant acquisition settings. ImageJ software was used to measure intensities of
ﬂuorescence on planar projections of confocal raw images spanning 6 µm. Elliptical
regions of interest encompassing the soma of each DiI-positive neuron were
deﬁned in the DAPI image to exclude staining of the nucleus. The measurements
were repeated in an adjacent area out of the tissue and the resulting background
intensities were subtracted from the soma ﬂuorescence signal. Results are expressed
as mean grey value intensity per pixel meaning the sum of grey values of all pixels
in the ROI divided by the number of pixels.
PKA western blot analysis. TGs were collected at 21 days after sumatriptan or
saline infusion (T0), scrapped in TE buffer (66 mM Tris pH 6.8, 2% SDS, 10%
glycerol, 0.1 M DTT, and antiprotease 2×) and sonicated 3 × 5 s. The protein
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concentration was analyzed by spectrophotometer (Nanodrop); concentrations
were normalized to 800 µg/ml in TE and bromophenol blue (30 mM). Electro-
phoresis was performed via SDS–PAGE using bis/tris polyacrylamide gels 4–12%
(Thermo Scientiﬁc). After blotting, nitrocellulose membranes were stained with
ponceau red. For immunostaining, membranes were washed in TBST, blocked in
blocking solution (5% milk in TBST) and incubated with anti-PKA (rabbit
monoclonal, 1:5000, Abcam, ab75991) and anti-GAPDH (mouse monoclonal,
1:5000, Millipore, MAB374) antibodies overnight at 4 °C. The next day, the
membranes were washed three times in TBST, incubated with secondary
polyclonal-HRP-conjugated goat anti-rabbit (1:2000, Biorad, 1706515) or anti-
mouse (1:2000, polyclonal, Biorad, 1706516) antibody for 1 h at RT and washed
again three times in TBST. Afterward, immunoreactivity was visualized using ECL
Western blotting substrate (Roche) and densitometrically quantiﬁed using a Gbox
Analyzer (Syngene). Reported mean grey values were determined with ImageJ.
CGRP secretion. TGs were dissected out at day 21 and cultured for 1 DIV. Cells
were plated in ﬂat bottom plates at a concentration of 15,000 cells per well. The
supernatant of cultured TG neurons was removed for CGRP detection after 30 min
incubation with KCl (40 mM), SNP (1 mM), or the vehicle (0.9% NaCl). CGRP
detection was made using an enzyme-linked immunoabsorbent assay kit (Spibio,
Berlin Pharma, France). Samples were run in triplicate.
Laser Doppler blood perfusion scanning. Meningeal microcirculation was
determined in isoﬂurane-anesthesized mice with a laser Doppler blood perfusion
scanner (Periscan PIM-III, Perimed) through the closed cranium after removing
the covering skin and the periosteum. Light particles that hit moving blood cells
undergo a change in wavelength/frequency, while light particles which encounter
static structures return unchanged. The scattered light that returns to the tissue
surface is registered by a photodetector. The perfusion can be calculated since the
magnitude and frequency distribution of the Doppler shifted light are directly
related to the number and velocity of blood cells, but unrelated to their direction of
movement. Although the measured parameter is ﬂux, this signal is then processed
to extract information about the microcirculatory blood ﬂow. After a control
period (10 min), SNP (0.03 mg/kg) was injected into the jugular vein catheter and
the observation period lasted for 90 min.
Quantitative real-time RT-PCR. Total RNA was extracted from TG tissue using
the RNeasy®Plus minikit (Qiagen) and assessed on a NanoDrop ND-2000 spec-
trophotometer (Thermoscientiﬁc) for concentration (A260) and purity by OD ratios
(A260/A280, ranging between 2.0 and 2.2). cDNA was synthesized by using 1.2 µg
total RNA from each sample with oligo-dT primers and Superscript III® (Invi-
trogen) in 20 µl reactions according to the manufacturer’s instructions. To assess
the speciﬁcity of these reactions, no reverse transcriptase and no template controls
were also generated. cDNA was stored at −20 °C before PCR detection. RT pro-
ducts were diluted and ampliﬁed in 12 µl reactions using Kapa Sybr® Fast qPCR
kits (Kapa Biosystems). GAPDH was selected as reference gene for normalization
of the qPCR results. qPCR reactions were run in duplicate on a Applied Biosystems
7500 Fast Real-time PCR thermocycler using MicroAmp® Fast 96-well reaction
plates. Thermocycling parameters were 40 cycles of 95 °C for 3 s for denaturation
and 60 °C for 30 s for annealing and extension. Parameters and reaction conditions
were identical for all sets of primers. To compare transcript levels between saline
and sumatriptan TG samples, the relative quantiﬁcation (RQ) method was used.
First, the difference (ΔCt) between the cycle threshold (Ct) values of the target
gene and the GAPDH gene was calculated. Then, the difference (ΔΔCt) between
the normalized values with or without sumatriptan was calculated: ΔΔCt=
ΔCtsumatriptan−ΔCtsaline. Finally, to determine the ratio of expression levels in
sumatriptan samples versus saline samples, we used the RQ formula as follows
RQ= 2 −ΔΔCt. Applied Biosystems 7500 Software v 2.0.6 was used for analysis.
Primers used were described in Table 1.
Statistical analysis. All values are shown as mean ± standard error of the mean
(SEM) and n represents the number of animals or cells examined. Except for some
behavioral experiments, no statistical methods were used to pre-determine sample
sizes but our sample sizes are similar to those reported in previous publications.
Assessment of normality for sample >14 was tested using the
Kolmogorov–Smirnov or the D’Agostino–Pearson Omnibus K2 normality test.
Tests for differences between two normally distributed populations were performed
using two-tailed t-test. Small sample size lacks power to test normality, therefore
we typically used non-parametric Mann–Whitney test and Wilcoxon’s test to test
for differences between two populations in small samples (n ≤ 15). Two-way
(repeated measures) ANOVA followed by Student–Newman–Keuls multiple
comparison procedure was used for experiments with multiple groups and two
dependent variables. Figure legends specify which test was used for speciﬁc
experiments. Signiﬁcant levels were set at p ≤ 0.05. Analysis used a combination of
Clampﬁt 9.2 (Molecular Devices), Origin 7.0 (OriginLab), and PRISM 7.0
(GraphPad) softwares.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all the data supporting the ﬁndings of this study are included in
the article (or in the Supplementary material) and available from the corresponding
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